Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P)

MLA

Dax Torti, et al. “Bespoke Circulating Tumor DNA (CtDNA) Analysis as a Predictive Biomarker in Solid Tumor Patients (Pts) Treated with Single-Agent Pembrolizumab (P).” Journal of Clinical Oncology, vol. 37, May 2019, p. 2542. EBSCOhost, https://doi.org/10.1200/jco.2019.37.15_suppl.2542.

APA

Dax Torti, Wei Xu, Alexey Aleshin, Aaron R. Hansen, Hsin-Ta Wu, Himanshu Sethi, Lillian L. Siu, Albiruni Ryan Abdul Razak, Cindy Yang, Zhihui (Amy) Liu, Marco A. J. Iafolla, Trevor J. Pugh, Philippe L. Bedard, Scott V. Bratman, Maggie C. Louie, Svetlana Shchegrova, Scott Dashner, Anna Spreafico, Stephanie Lheureux, & Pamela S. Ohashi. (2019). Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P). Journal of Clinical Oncology, 37, 2542. https://doi.org/10.1200/jco.2019.37.15_suppl.2542

Chicago

Dax Torti, Wei Xu, Alexey Aleshin, Aaron R. Hansen, Hsin-Ta Wu, Himanshu Sethi, Lillian L. Siu, et al. 2019. “Bespoke Circulating Tumor DNA (CtDNA) Analysis as a Predictive Biomarker in Solid Tumor Patients (Pts) Treated with Single-Agent Pembrolizumab (P).” Journal of Clinical Oncology 37 (May): 2542. doi:10.1200/jco.2019.37.15_suppl.2542.